Role of oral Coenzyme Q supplementation in children with migraine
Not Applicable
- Conditions
- Health Condition 1: G439- Migraine, unspecified
- Registration Number
- CTRI/2020/07/026271
- Lead Sponsor
- ICMR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Children with age 6-18 years
2.Newly diagnosed to have migraine with/without aura
3.Not received any medication for migraine prophylaxis in the past three months
4.Caregivers giving informed consent
Exclusion Criteria
1.Already on other prophylactic treatment for migraine
2.Receiving any antioxidant/other herbal medication/nutraceuticals in the past three months
3.Any major systemic illnessAny other associated neurological disorder
4.Abnormality in neuroimaging (MRI brain/CT brain)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Comparison of the reduction in the number of headache days per month at baseline for the 3 months prior to study initiation as compared to the last 4 weeks of treatment in both arms. It will be determined by reviewing the headache diary maintained by the patient and caregivers.Timepoint: 24 weeks
- Secondary Outcome Measures
Name Time Method